Gastric Cancer Drug Discoveries: what the future holds

Date: March 31, 2011
Pages: 158
Price:
US$ 2,615.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G39B2F626ABEN
Leaflet:

Download PDF Leaflet

Gastric Cancer Drug Discoveries: what the future holds
Original analysis of the clinical potential and commercial prospects for companies, launched products and pipeline candidates put into current market context.

The market is set for rapid and significant growth

There is room for considerable change in the gastric cancer market as improved therapies seek to improve patient outcomes for advanced disease. Over the next seven years, Espicom expects to see the market grow by 133% from US$846 million in 2010, to US$1.97 billion in 2017, with the targeted therapies accounting for most of this growth. While competition amongst these targeted therapies will intensify from 2013/4, Roche will continue to dominate this market with Herceptin, which was recently approved in Japan.

Next generation chemotherapy

While targeted therapies are expected to grow rapidly, it is chemotherapy agents which are leading the current market. One notable success of recent years is Roche’s Xeloda, which is replacing 5-FU in the US and EU, where it has been approved as a first-line treatment in gastric cancer since March 2007. With US patents in force until 2013, Xeloda is the only branded chemotherapeutic for gastric cancer not facing generic competition at present.

The rise of targeted therapies

Espicom believes that by 2017, targeted therapies will account for over 60% of the gastric cancer market. Competition for Herceptin will initially come from GSK’s Tykerb/Tyverb, but Roche’s Avastin, Merck’s Erbitux and Lilly’s ramucirumab are just some of those waiting in the wings over the coming period. One of the most promising candidates is Bayer’s Nexavar where very promising PII trial results have given optimism for its prospects.

Critical Business Insights from this report which...

Provides independent, reliable 7-year forecasts, market share and unique product scoring which give you real insights to the current and future business landscape

Evaluates the competitive environment – assess winners and losers and know their pipeline content and status

Covers major launched products and significant pipeline candidates

Identifies promising mid-stage development candidates

Forecasts the launch timeframe for new products or indications

Summarises current clinical thinking on gastric cancer
EXECUTIVE SUMMARY

MARKET ANALYSIS

Current Market
  Next-Generation Chemotherapy
  Targeted Therapy
Future Market

SALES FORECASTS

COMPETITIVE ANALYSIS

Competitor Ratio Analysis

RESEARCH AND DEVELOPMENT

VEGF Pathway Inhibitors
EGFr Inhibitors
Other Targeted Therapies of Interest
Chemotherapy

BACKGROUND INFORMATION

What is Gastric Cancer?
The Stages of Gastric Cancer
Survival Rates
Risk Factors for Gastric Cancer
Preventing Gastric Cancer
Current Treatments
  Surgery
  Chemotherapy
  Radiation Therapy
Why are New Treatments Needed?
Patient Statistics

GASTRIC CANCER PRODUCTS

TARGETED THERAPIES

Approved Products
  Herceptin
Phase III Products
  Afinitor
  Avastin
  Erbitux
  Ramucirumab
  Tykerb/Tyverb
Phase II Products
  AMG
  AMG
  ARQ
  AUY922
  GDC-0449
  Nexavar
  Nimotuzumab
  Olaparib
  Telatinib
  Tremelimumab
  TSU-68
  Vectibix
Phase I Products
  Axitinib
  BMS-833923
  Brivanib
  CUDC-101
  Recentin
  Vandetanib

CHEMOTHERAPY

Approved Products
  Taxotere
  Teysuno
  Xeloda
Phase II Products
  Alimta
  Ixempra
  Tesetaxel

APPENDIX

Phase Transition Probability
Source Material

LIST OF TABLES

The Potential Launch Landscape for Gastric Cancer
Gastric Cancer Sales Forecasts (2010-2017)
Competitor Ratio Analysis Scores
Drugs in Clinical Development for Gastric Cancer
TNM Stage Grouping
Five-year Gastric Cancer Survival Rates (US)
Targeted Therapies for Gastric Cancer
Chemotherapy for Gastric Cancer
Herceptin Sales by Company (2009-2017)
Herceptin Sales by Indication (2009-2017)
Afinitor Sales by Indication (2009-2017)
Avastin Sales by Company (2009-2017)
Avastin Sales by Indication (2009-2017)
Erbitux Sales by Company (2009-2017)
Erbitux Sales by Indication (2009-2017)
Ramucirumab Sales by Indication (2014-2017)
Tykerb/Tyverb Sales by Indication (2009-2017)
Studies in Metastatic CRC with EGFr-Targeting Monoclonal Antibodies in Irinotecan-Refractory Patients
Safety Profiles of Leading Anti-EGFr Products and Nimotuzumab
Efficacy of Docetaxel in the Treatment of NSCLC Patients Previously Treated with a Platinum-Based CT Regimen (Intent-to-Treat Analysis) �
Taxotere Sales by Indication (2009-2017)
S-1 Sales (2009-2017)
Xeloda Sales by Company (2009-2017)
Xeloda Sales by Indication (2009-2017)
Probability of Launch

LIST OF CHARTS

Gastric Cancer Sales by Therapy (2010)
Market Share by Product (2010)
Market Share of Gastric Cancer Therapies (2010)
Market Share of Gastric Cancer Therapies (2017)
Market Share by Product (2017)
Major Players in Gastric Cancer by Market Share (2010)
Major Players in Gastric Cancer by Market Share (2017)
Competitor Ratio Analysis Scores
HER2 Signalling Pathway
Herceptin Sales (2009-2017)
Afinitor Mode of Action
Afinitor Sales (2009-2017)
Avastin Mode of Action
Avastin Sales by Company (2009-2017)
Avastin Sales by Indication, 2010
Avastin Sales by Indication, 2017
Erbitux Sales (2009-2017)
Ramucirumab Sales (2014-2017)
Tykerb/Tyverb Total Sales (2009-2017)
Tykerb Sales by Indication, 2017
AUY922 Mode of Action Within a Cancer Cell
Nexavar’s Dual Mode of Action
Schematic of EGFr Inhibition in Tumourigenesis
TAX 317 Survival K_M Curves - Docetaxel 75mg/m2 vs Best Supportive Care
TAX 320 Survival K_M Curves - Docetaxel 75mg/m2 vs Vinorelbine or Ifosfamide Control
Taxotere Sales (2009-2017)
Taxotere Sales by Indication (2010)
Taxotere Sales by Indication (2017)
S-1 Sales (2009-2017)
Xeloda Sales (2009-2017)
Xeloda Sales by Indication (2010)
Xeloda Sales by Indication (2017)
Skip to top


Blood Cancer Drug Discoveries: what the future holds US$ 2,265.00 Apr, 2008 · 245 pages
Breast Cancer Drug Discoveries: What the Future Holds US$ 3,145.00 Aug, 2011 · 382 pages
Prostate Cancer Drug Discoveries: What the Future Holds US$ 2,265.00 Nov, 2009 · 160 pages
Obesity Drug Discoveries: what the future holds US$ 1,740.00 Aug, 2007 · 116 pages

Ask Your Question

Gastric Cancer Drug Discoveries: what the future holds
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: